Abstract

Relevance.Cervical cancer (CC) continues to be the focus of attention of oncologists all over the world due to the fact that the incidence of it over the past decades has not tended to decrease. The steady increase in morbidity, high mortality rates, and the tendency to «rejuvenate» the disease, the relatively low detection rate of the early stages of the disease due to poor results of cytological screening predetermine the search for new scientifically based approaches to solving cervical cancer problems. A promising direction for the prevention of squamous cell carcinoma and adenocarcinoma associated with human papillomavirus (HPV) is prophylactic vaccination against HPV, the need for which is due to the role of HPV infection in carcinogenesis processes.The aimof this article is to summarize the currently available data on advances in the prevention of precancerous lesions and cervical cancer, primarily through vaccination against HPV infection.Conclusions.The creation of vaccines for the prevention of oncogenic HPV types is a significant achievement in the biomedical research area. The successful development of a group of vaccines, which can confidently be called the vaccines of the 21st century, gives us hope that modern medicine has the potential to reduce population cancer risk and reduce the likelihood of early onset of cervical cancer. Demonstration of the efficacy and feasibility of routine HPV vaccination programs in a number of countries demonstrates encouraging progress in solving cervical cancer problems. Vaccination against HPV will not only ensure epidemiological well-being, but also lead to a decrease in morbidity and mortality from such a terrible complication of human papillomavirus infection – cervical cancer.

Highlights

  • Москва 3 ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И

  • A promising direction for the prevention of squamous cell carcinoma and adenocarcinoma associated with human papillomavirus (HPV) is prophylactic vaccination against HPV, the need for which is due to the role of HPV infection in carcinogenesis processes

  • The creation of vaccines for the prevention of oncogenic HPV types is a significant achievement in the biomedical research area

Read more

Summary

Рак влагалища Vaginal cancer

Примечание: ЦИН – цервикальная интраэпителиальная неоплазия Note: CIN – cervical intraepithelial neoplasia женщин проводили сравнительный анализ частоты случаев ВПЧ типов 16, 18, ассоциированных с CIN 2+. Показали отсутствие новых случаев патологии цервикального эпителия за длительный период наблюдения Продемонстрирована продолжительная защита женщин, вакцинированных тетравалентной ВПЧ вакциной, в течение, по меньшей мере, 10 лет с тенденцией сохранения непрерывной защиты вплоть до 12 лет последующего наблюдения [27,28]. В Финляндии, где национальная программа вакцинации против ВПЧ стартовала в 2013 г. Количество и частота различных видов инвазивного рака, ассоциированных с ВПЧ, среди вакцинированных и невакцинированных женщин 14 лет и старше [24] Table 2. The number and frequency of various types of HPV-associated invasive cancer among vaccinated and unvaccinated women 14 years of age and older [24]

Орофарингеальный рак Oropharyngeal cancer
Findings
Complete vaccination
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call